Tegoprazan

Products

We are here to help in anything you need. Please use our online system or send an email to .

Tegoprazan

Inquiry

Catalog Number	PR942195553
CAS	942195-55-3
Synonyms	CJ-12420; RQ-00000004
Molecular Weight	387.38
Molecular Formula	C20H19F2N3O3
Purity	>99%
Color	Off-white to light yellow
Drug Categories	Alimentary Tract and Metabolism; Drugs for Acid Related Disorders; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Gastric Acid Lowering Agents; Proton Pump Inhibitors
Drug Interactions	Alendronic acid-The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Tegoprazan. Amphetamine-Tegoprazan can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. Amprenavir-Tegoprazan can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. Asunaprevir-Tegoprazan can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy. Atazanavir-Tegoprazan can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Physical State	Solid
Type	Small Molecule

Pharmacology

Mechanism of Action

Tegoprazan operates as a highly selective and potent potassium-competitive acid blocker, distinguishing itself from traditional proton-pump inhibitors through its unique mechanism of action. Unlike proton-pump inhibitors, Tegoprazan does not necessitate conversion into an active form. It directly targets and reversibly inhibits the H+/K+-ATPase enzyme in a potassium-competitive manner. This efficacy is attributed to Tegoprazan's properties as an acid-resistant weak base, which allows it to persist effectively in the highly acidic environment of gastric parietal cell canaliculi.

It should be noted that our service is only used for research, not for clinical use.